(untitled) - Angevin, E; Lopez-Martin, J A; Lin, C C (Clin Cancer Res, 2013)
Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma